Oculus introduces Microcyn wound care for US podiatry market

The company said that the product, which has received three FDA 510(k) clearances for use in moistening, lubricating, cleaning and debriding wounds, is available to podiatrists for treatment of, and distribution to, their patients.

The company contracted a professional marketing and sales management group to spearhead a 10-member sales force in the initial sales effort. Each sales representative’s efforts will be supported by advisory boards consisting of practicing podiatrists in their respective sales territory. Upon successful completion of this multiregion introduction, the company plans to expand marketing efforts into other US regions, reaching the more than 15,000 podiatrists in the US.

Oculus is also pursuing a US drug approval using a different formulation of the Microcyn technology. The company intends to secure a partner that will assume clinical, regulatory and commercial responsibilities along with costs for the drug formulation approval. Microcyn wound care is available in 8oz and 500ml bottles.

Hoji Alimi, CEO and founder of Oculus, said: “Based upon our clinical trial success and positive feedback from our sampling program to US physicians over the past year, we have generated valuable insights into how medical professionals use Microcyn to treat patients.

“Podiatry was one of the areas in which we witnessed significant patient benefits and positive physician response. By using the services of a contract sales organization, we’re able to effectively launch Microcyn in the US while continuing to reduce our overall expenses.”